PR Newswire
WASHINGTON, Aug. 30, 2016
WASHINGTON, Aug. 30, 2016 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the United States Patent and Trademark Office (USPTO) Patent
Trials and Appeal Board declined the request by Roxane Laboratories, Inc. (Roxane) to institute an inter partes review of
U.S. Patent No. 9,138,432 ("the '432 patent"). The '432 patent was issued by the USPTO in September
2015 and expires in September 2025.
Vanda had previously announced on August 25, 2016 that Judge Gregory M. Sleet of
the United States District Court for the District of Delaware ruled that Roxane infringed U.S. Patent Nos. RE39,198
("the '198 Patent") and 8,586,610 ("the '610 Patent") and accordingly issued an injunction barring Roxane from marketing its
product until the expiration of the later expiring '610 patent on November 2, 2027.
About Vanda Pharmaceuticals Inc.
Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to
address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals, please
visit www.vandapharma.com.
Fanapt® is a registered trademark of Vanda Pharmaceuticals Inc.
Corporate Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
Media Contact:
Laney Landsman
Group Vice President
Makovsky
(212) 508-9643
llandsman@makovsky.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/uspto-dismisses-petition-for-inter-partes-review-of-fanapt-patent-300320203.html
SOURCE Vanda Pharmaceuticals Inc.